



Hifax EKC 244X 1 Black

Compounded Polyolefin

Product Description

Hifax EKC 244X 1 Black is a 40% talc filled, impact modified concentrate. This grade can be used in combination with Hifax EP 3080 as open compound concept.

Product Characteristics

Status	Commercial: Active
Test Method used	ISO
Processing Methods	Injection Molding
Typical Customer Applications	Bumpers

Typical Properties	Method	Value Unit
Physical		
Density	ISO 1183	1,23 g/cm ³
Melt flow rate (MFR) (230°C/2.16Kg)	ISO 1133	2,0 g/10 min

Notes

Typical properties; not to be construed as specifications.

© LyondellBasell Industries Holdings, B.V. 2012

LyondellBasell markets this product through the following entities:

- 1 Equistar Chemicals, LP
- 1 Basell Sales & Marketing Company B.V.
- 1 Basell Asia Pacific Limited
- 1 Basell International Trading FZE
- 1 LyondellBasell Australia Pty Ltd

For the contact details of the LyondellBasell company selling this product in your country, please visit <http://www.lyondellbasell.com/>.

Before using a product sold by a company of the LyondellBasell family of companies, users should make their own independent determination that the product is suitable for the intended use and can be used safely and legally. SELLER MAKES NO WARRANTY; EXPRESS OR IMPLIED (INCLUDING ANY WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR ANY WARRANTY) OTHER THAN AS SEPARATELY AGREED TO BY THE PARTIES IN A CONTRACT.

This product(s) may not be used in:

- (i) any U.S. FDA Class I, Health Canada Class I, and/or European Union Class I medical devices, without prior notification to Seller for each specific product and application; or
- (ii) the manufacture of any of the following, without prior written approval by Seller for each specific product and application: U.S. FDA Class II medical devices; Health Canada Class II or III medical devices; European Union Class II medical devices; or any equivalent U.S. FDA, Health Canada, or European Union regulations pertaining to medical devices; packaging in direct contact with a pharmaceutical active ingredient and/or dosage form; and tobacco-related products and applications. This product(s) may not be used in the manufacture of any of the following applications: U.S. FDA Class III medical devices; Health Canada Class IV medical devices; European Class III medical devices; applications involving permanent implantation into the body; life-sustaining medical applications; and lead, asbestos or MTBE related applications. All references to the U.S. FDA, Health Canada and European Union regulations include another country's equivalent regulatory classification.

Users should review the applicable Material Safety Data Sheet before handling the product.

Addhere, Adflex, Adstif, Adsyl, Akoafloor, Akoalit, Alathon, Alkylate, Amazing Chemistry, Aquamarine, Aquathene, Arconate, Arcopure, Arcosolv, Arctic Plus, Arctic Shield, Avant, Catalloy, Clyrell, CRP, Crystex, Dexflex, Duopac, Duoprime, Explore & Experiment, Filmex, Flexathene, Glacido, Hifax, Histif, Hostacom, Hostalen, Ideal, Integrate, Koattro, LIPP, Lucalen, Luflexen, Lupolen, Lupolex, Luposim, Lupostress, Lupotech, Metocene, Microthene, Moplen, MPDIOL, Nerolex, Nexprene, Petrothene, Plexar, Polymeg, Pristene, Prodflex, Pro-Fax, Punctilious, Purell, SAA100, SAA101, Sequel, Softell, Spherilene, Spheripol, Spherizone, Starflex, Stretchene, Superflex, TBAC, Tebol, T-Hydro, Toppyl, Trans4m, Tufflo, Ultrathene, Vacido and Valtec are trademarks owned or used by the LyondellBasell family of companies.

Adsyl, Akoafloor, Akoalit, Alathon, Aquamarine, Arconate, Arcopure, Arcosolv, Arctic Plus, Arctic Shield, Avant, CRP, Crystex, Dexflex, Duopac, Duoprime, Explore & Experiment, Filmex, Flexathene, Hifax, Hostacom, Hostalen, Ideal, Integrate, Koattro, Lucalen, Lupolen, Microthene, Moplen, MPDIOL, Nexprene, Petrothene, Plexar, Polymeg, Pristene, Pro-Fax, Punctilious, Purell, Sequel, Softell, Spheripol, Spherizone, Starflex, Tebol, T-Hydro, Toppyl, Tufflo and Ultrathene are registered in the U.S. Patent and Trademark Office.

Release Date: 23 Aug 2013